🇺🇸 FDA
Patent

US 9511103

AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

granted A61KA61K35/76A61K35/761

Quick answer

US patent 9511103 (AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K35/76, A61K35/761, A61K38/1703, A61K48/005